Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Check out some of our latest original content that was created and distributed as part of our ongoing collaborations with IR firms and other companies.

MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Spotlighted in Upcoming Virtual Investor Lunch Break Event

Posted on April 22, 2024 by MissionIR

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be featured on the Virtual Investor Lunch Break: The CNSP Opportunity event. During the live video webcast, which is scheduled to begin at 12 p.m. EST, CEO John Climaco will present a corporate overview. He will also discuss the company’s business outlook and opportunity. In addition, the event provides an opportunity for those participating to submit questions; Climaco will answer as many questions as possible I the time provided. A replay of the presentation will be available for 90 days shortly after the presentation has ended.

To view the full presentation, visit https://ibn.fm/16Sc3

To view the full press release, visit https://ibn.fm/zGK7v

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anticancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information about the company, please visit www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in CNS Pharmaceuticals Inc. CNSP, Small Cap News | Leave a comment

Lexaria Bioscience Corp. (NASDAQ: LEXX) Marks GLP-1 Study Milestone with Ethics Review Board Approval

Posted on April 22, 2024 by MissionIR
  • Lexaria, a global innovator in drug delivery platforms, has received approval for its GLP-1 human pilot study #2 by an independent third-party ethics review board
  • GLP-1 drugs are utilized in the treatment of type 2 diabetes and obesity, a huge market, and are typically administered by painful and expensive injection, offering a major opportunity for Lexaria’s oral delivery platform
  • This approval sets the company up for dosing within 30 days or less, with tentative study completion dates for this summer
  • The study will comprise two study arms, the second study arm will investigate whether Lexaria’s patented DehydraTECH(TM)-enhanced semaglutide can effectively absorb into the sublingual/buccal tissues of the mouth with fewer side effects
  • For Lexaria, this milestone brings it closer to its objective of forging strategic partnerships with leading industry players, ultimately growing shareholder value

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced approval for its GLP-1 human pilot study #2 by an independent third-party ethics review board. The potential use of Lexaria’s oral delivery platform for GLP-1 drugs, typically administered by injection or stomach-upsetting tablets, represents a massive market opportunity. This study approval marks a milestone for the company, with the first dosing set to begin within 30 days or less, and with tentative completion dates for this summer (https://ibn.fm/XSHbz).

The human pilot study will seek to explore Lexaria’s patented DehydraTECH(TM) technology and its overall effectiveness in the delivery of glucagon-like peptide-1 (“GLP-1”). It will involve up to 9 healthy volunteers and feature two study arms, each evaluating tolerability, blood absorption levels, and blood sugar control.

The first study arm will use a Rybelsus(R) composition processed with DehydraTECH and delivered within swallowed capsules. The second arm will explore an oral dissolvable tablet formulation with DehydraTECH-powered semaglutide from Rybelsus(R). This will mark the very first study design to investigate whether DehydraTECH-enhanced semaglutide can effectively absorb into the sublingual/buccal tissues of the mouth and throat with fewer side effects than from swallowed administration and with some adequate level of blood absorption.

Earlier in March, Lexaria announced having hired a contract research organization (“CRO”) to perform this specific study, described as a randomized, crossover, placebo-controlled investigation (https://ibn.fm/Qgmg3). This ethics review board approval is a testament to the steady progress of the company. It also allows Lexaria to maintain its current momentum by meeting the study objectives and realizing the timelines set out at the beginning of the year. More importantly, these milestones inch the company closer to forging strategic partnerships with leading industry players, which would be integral in growing shareholder value.

“I am excited about this Study; the Lexaria scientific team believes that a dissolvable oral tablet that delivers an effective fraction of semaglutide along with reduced side effects could potentially offer valuable benefits to the pharmaceutical industry that might lead to a higher likelihood of favorable strategic partnering with leading industry players in GLP-1,” noted Chris Bunka, Lexaria’s CEO.

“Most GLP-1 drugs sold today are administered by painful and expensive injection devices. More effective and tolerable oral delivery of GLP-1 drugs could be extremely valuable to patients and to industry,” he added.

Previous studies have demonstrated DehydraTECH’s ability to improve the delivery of certain drugs destined for the bloodstream. Lexaria hopes to replicate these results in this study to usher in a new era in GLP-1 delivery without the need for painful injections or stomach-upsetting tablets. Its management is optimistic about the study results, and the ethics review board approval brings the company closer to realizing this objective.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

Clene Inc. (NASDAQ: CLNN) Continues Development of Lead Drug Candidate CNM Au8(R) for Neurodegenerative Diseases including Parkinson’s Disease

Posted on April 22, 2024 by MissionIR
  • CNM-Au8 is an oral suspension with demonstrated activity in restoring neuronal health and function by increasing energy production and utilization
  • Treatment with CNM-Au8 investigated in clinical trials adjunctive to standard-of-care exhibits no known drug interactions, and aims to enhance function and survival
  • Nearly 90,000 people are diagnosed with Parkinson’s disease every year with no approved drug to slow or halt disease progression currently available
  • The Parkinson’s disease treatment market was valued at $4.61 billion in 2022 and is expected to reach $11.98 billion by 2030

In recognition of April as Parkinson’s Disease Awareness Month, IBN is highlighting Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including Parkinson’s disease (“PD”), amyotrophic lateral sclerosis (“ALS”), and multiple sclerosis (“MS”). Clene is developing its lead drug candidate CNM-Au8(R) for potential treatment of these neurodegenerative diseases. CNM-Au8 is an oral suspension designed to restore neuronal health and function by increasing energy production and utilization by driving critical cellular energy-producing reactions that enable neuroprotection and remyelination. The result is an increase in neuronal and glial resilience to disease-relevant stressors.

In March 2021, Clene was awarded a grant from The Michael J Fox Foundation for Parkinson’s Research (“MJFF”) to accelerate the development of CNM-Au8 as a treatment for PD. The funding supports efficacy studies in a human cell culture model of PD that utilizes skin cells from individuals with PD. The cells are then converted in the laboratory to dopaminergic neurons that exhibit many aspects of the disease state. The research, led by Karen Ho, PhD, VP Translational Medicine at Clene, was a collaboration with Dr. Jerome Mertens while he was Assistant Professor at the University of Innsbruck (currently Associate Professor in the Department of Neurosciences of the University of California, San Diego) and is currently a collaboration with Dr. Fred (“Rusty”) Gage, Vi and John Adler Chair for Research on Age-Related Neurodegenerative Disease, Professor of Genetics of the Salk Institute. These two scientists are world-renowned researchers who pioneered the specific techniques to generate the human cell model utilized for the project. The team is exploring multiple aspects of the effects of CNM-Au8 on PD neurons, including potential improvements in mitochondrial function and effects on transcriptomic profiles in comparison to untreated healthy and disease controls. Results from the study are expected in Q2 2024.

The peer-reviewed publication, “Evidence of brain target engagement in Parkinson’s disease and multiple sclerosis by the investigational nanomedicine, CNM-Au8, in the REPAIR phase 2 clinical trials,” was published in Journal of Nanobiotechnology in December 2023 (https://link.springer.com/article/10.1186/s12951-023-02236-z). The study demonstrated that oral daily doses of CNM-Au8 over 12 weeks leads to increased levels of brain metabolites associated with improved mitochondrial function and brain health in these diseases.

Over 600 cumulative years of CNM-Au8 patient exposure across ALS, MS, and PD trials and compassionate use programs have shown no safety concerns. With safety, early efficacy, and brain target engagement data in hand for PD, Clene is advancing CNM-Au8’s development as a potential first-in-class treatment for PD.

A Parkinson’s Foundation-backed study in 2022 found that nearly 90,000 people are diagnosed with Parkinson’s disease every year – which is approximately the amount of fans at the Rose Bowl Stadium. This number represents a 50% increase from the previous estimated rate of 60,000 diagnoses annually.

“These updated estimates of incidence are necessary for understanding disease risk, planning health care delivery, and addressing care disparities,” said James Beck, Ph.D., Parkinson’s Foundation Chief Scientific Officer (https://ibn.fm/0xzdX). “Knowing this information will allow us to better serve people with Parkinson’s and their families and plan for adequate health care services in the future.”

The Parkinson’s disease treatment market was valued at $4.61 billion in 2022. It is expected to grow at a CAGR of 12.1%, resulting in an estimated value of $11.98 billion by 2030. The market’s growth is supported by the increasing geriatric population, the high burden of Parkinson’s disease in Western countries, and the strong product pipeline of disease-modifying therapies. It is estimated that Parkinson’s disease affects around 1% of the total population aged 60 years and older and rises to 5% for 85 years and older (https://ibn.fm/3ySss).

CNM-Au8(R) is a federally registered trademark of Clene Nanomedicine, Inc.

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in Clene Inc. CLNN | Leave a comment

D-Wave Quantum Inc. (NYSE: QBTS) Announces Dates for Qubits 2024 Quantum Computing Conference in Boston

Posted on April 22, 2024 by MissionIR
  • D-Wave’s Qubits 2024 annual quantum computing conference will take place in Boston, Massachusetts, on June 17 and 18, 2024
  • The two-day event will explore the transformative potential of D-Wave’s quantum technologies as they tackle complex computational challenges across supply chain logistics, manufacturing, government, and the life sciences sectors
  • Participants will learn about D-Wave customers’ powerful quantum-hybrid applications, the company’s latest quantum technology innovations, and updates on the company’s latest groundbreaking scientific research

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services and the world’s first commercial supplier of quantum computers, recently announced that its Qubits 2024 quantum computing conference will take place in Boston, Massachusetts, on June 17 and 18, 2024. The conference theme will be “Success, Powered by Quantum.” It will demonstrate how D-Wave, partners, and customers such as Momentum Worldwide (part of Interpublic Group), Los Alamos National Lab, Zapata AI, and others are achieving measurable outcomes with D-Wave’s innovative annealing quantum computing technology (https://ibn.fm/cmO6R).

This two-day event will delve into the transformative potential of D-Wave’s quantum technologies as they tackle complex computational challenges across supply chain logistics, manufacturing, government, and the life sciences sectors. The agenda will feature live demonstrations of quantum advancements, product updates, an overview of the company’s most recent scientific achievements, and insights into customer projects, spanning ongoing developments and active deployments.

“We are thrilled to bring Qubits to the global innovation hub of Boston this year, where we will share the incredible momentum we are seeing as our quantum technologies cross the chasm from experimentation to operational use,” said Dr. Alan Baratz, CEO of D-Wave. “This is the must-attend event of the year for anyone looking to understand how today’s quantum technology is transforming business, especially as it merges with AI to fuel the next generation of groundbreaking applications.”

D-Wave will offer a free live stream of the first day’s morning talks, allowing participants worldwide to virtually attend. To register for Qubits, visit www.qubits.com.

For more information, visit the company’s website at www.DWaveQuantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of the company’s most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of the company’s Quarterly Reports on Form 10-Q and in the company’s other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to the company on the date hereof. The company undertakes no duty to update this information unless required by law.

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in D-Wave Quantum Inc. QBTS | Leave a comment

SUIC Worldwide Holdings Ltd. (SUIC) Eyes Significant Share of Growing Global Supply Chain Financial Market with Proprietary All-in-One B2B2C System

Posted on April 22, 2024 by MissionIR
  • SUIC and Beneway USA have rolled out a proprietary B2B2C system, a superior all-in-one payment and total financing solution that combines the capabilities and benefits of SUIC’s B2B e-commerce model with those of its proprietary B2C platform
  • The B2B model streamlines business processes and enables businesses to develop and implement substantial growth opportunities as well as optimize costs
  • The all-in-one B2C platform integrates payment systems, electronic invoice devices, mobile cash registers, POS system devices, enterprise resource planning, big data, AI, value-added cloud services, and other services
  • SUIC hopes the B2B2C system, combined with cutting-edge technologies and solutions the company continues to adopt, will sustain rapid growth
  • The company is confident that the B2B2C system will not only boost the IPO activity of Beneway USA but also retain its strong momentum into Q2 2024

SUIC Worldwide Holdings (OTC: SUIC), SUIC is the largest shareholder and major operating partner of Beneway Holdings Group, Ltd. USA (“Beneway USA”), recently announced a positive development expected to boost the IPO activity of Beneway USA. The announcement focused on the capabilities of SUIC and Beneway USA’s proprietary B2B2C system (https://ibn.fm/2WJFP).

The B2B2C system is a superior all-in-one payment and total financing solution that combines the capabilities and benefits of SUIC’s B2B e-commerce model with those of its proprietary B2C platform. For its part, the B2B model enables businesses to develop and implement substantial growth opportunities as well as optimize costs. It streamlines business processes such as purchase order payments and inventory control and offers financing services, an AI credit system, and big data.

On the other hand, the B2C platform is an all-in-one product designed for merchants. Developed and offered by Boom FinTech Inc., a major fintech subsidiary of Beneway USA, the platform integrates payment systems, electronic invoice devices, mobile cash registers, POS system devices, enterprise resource planning, big data, AI, value-added cloud services, and other services. It allows merchants to use either the fully integrated system or just the functions and features they need. The platform is supported by nine fintech patents.

By combining the B2B model and the B2C platform, the company’s B2B2C system is the best of both worlds. It provides a platform that facilitates financing and other business operations, thus offering strategic planning functions that blend business financing and fintech solutions with inventory management systems. This, the company says, complements and bolsters sales and marketing channels of businesses’ partner merchants, franchisees, and suppliers around the world.

The B2B2C system is a result of various milestones SUIC and Beneway USA have progressively completed. For instance, SUIC and Boom Fintech recently entered into an agreement with BD Bankers to access credit of up to $100 million in Intellectual Property (“IP”) financing intended for the integration of advanced systems and patents held by Boom Fintech. According to the company, the IP financing will be used in the B2B financing of its merchants as well as to support their development of B2B technology. SUIC hopes the financing will bolster supply chain integration for suppliers (https://ibn.fm/nU64m).

Still, SUIC continues to adopt cutting-edge technologies and solutions to integrate its e-commerce operations within the global supply chain financing market. The company expects these technologies and solutions will sustain rapid growth driven by seamless digital payment methods and boost competition with brick-and-mortar establishments. In fact, the company intends to move into the major markets of the U.S., Europe, and other parts of the world as it builds a cohesive network, SUIC CEO Hank Wang said.

“Our comprehensive financial products and services are designed to advance our business strategies and solidify our equity value and future returns, especially for our shareholders. We expect that the borrowing and lending market will inflate up to 10 times the current supply chain financing market,” conveyed Mr. Wang, CEO of SUIC.

SUIC is confident that the B2B2C system will not only boost the IPO activity of Beneway USA but also retain its strong momentum into Q2 2024. It will also enable the company to tap into the growing global supply chain financial market, which is expected to reach $13.4 billion by 2025 from $6 billion in 2021, an 8.8% CAGR (https://ibn.fm/SUSrx). And with 60% of this market comprising small and medium-sized retailers, which constitute SUIC’s target market, according to the news release, the company is eying a significant share of the multi-trillion-dollar market.

For more information, visit the company’s website at www.SinoUnitedCo.com.

NOTE TO INVESTORS: The latest news and updates relating to SUIC are available in the company’s newsroom at https://ibn.fm/SUIC

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in SUIC Worldwide Holdings Ltd. SUIC | Leave a comment

MissionIRNewsBreaks – Correlate Energy Corp. (CIPI) Bringing Green Energy Solutions to Often Overlooked Segment

Posted on April 19, 2024 by MissionIR

Correlate (OTCQB: CIPI), a tech-enabled development, finance and fulfillment platform for distributed energy solutions across North America, aims to make solar power and other green energy solutions accessible to mid-tier companies that large energy companies and consulting firms in the sustainability market often overlook. “The company’s operational model involves identifying localized clean energy solutions and microgrids it can finance, develop and profitably sell to customers in business and residential circles while also retaining ownership of some energy systems that Correlate can use to sustain its own cash flow needs and build earnings for its shareholders… Correlate’s completed projects include the 26,000 individual solar panels atop the MGM Mandalay Resort in Las Vegas, which comprised the largest rooftop solar project (8.2 MW) west of the Mississippi when they were installed nearly a decade ago. Correlate has also completed a 12.9 MW system for Arizona State University that provides 71% of campus solar output to offset 15,600 tons of carbon dioxide each year, 6.48 MW for NFL stadiums in California, New York, Washington, and Massachusetts, and a 4.5 MW system for Albertsons-Safeway stores in California,” a recent article reads. “Solar’s the most applicable technology. Right now, it’s basically beating the grid for cost,” CEO Todd Michaels is quoted as saying.

To view the full article, visit https://ibn.fm/dppi5

About Correlate Energy Corp.

Correlate is a publicly traded company strategically positioned to capitalize on America’s unstoppable trend toward decentralized energy generation. The company employs a three-pronged strategy to create stockholder value from this multitrillion-dollar trend. First, Correlate seeks to finance, develop and profitably sell localized clean energy solutions and microgrids to industrial, commercial and residential customers. Secondly, Correlate plans to retain ownership of some of these energy systems and thereby realize ongoing, reliable cash flow. Third, Correlate seeks to acquire proven renewable energy companies in order to exponentially grow earnings per share for investors. Correlate’s management and board consist of industry experts who, during their careers, have successfully financed, developed and installed over two billion dollars of clean energy projects for their clients. For more information about the company, visit www.Correlate.Energy/investors.

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in Correlate Infrastructure Partners Inc. CIPI | Leave a comment

MissionIRNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Enters Into Private Placement Agreements to Raise Funds for Development of AVERSA Fentanyl

Posted on April 19, 2024 by MissionIR

Nutriband (NASDAQ: NTRB), a company engaged in the development of abuse-deterrent pharmaceutical products, has entered into definitive securities purchase agreements. The agreements are for the purchase and sale of up to 2,100,000 shares of common stock, with each share offered at $4 per share. According to the announcement, for each share of common stock purchased the investor receives a five-year warrant to purchase two shares of common stock; the exercise price for the warrants is $6.43 per share. The company anticipates using the funds from the private placement, which is expected to close on or about April 19, 2024, to complete the clinical development of its AVERSA(TM) Fentanyl, including the submission of a New Drug Application (“NDA”) with the U.S. Food and Drug Administration (“FDA”). Nutriband’s AVERSA Fentanyl could become the first-ever opioid patch with abuse-deterrent properties. “The completion of this private placement should provide sufficient funding through our NDA filing for AVERSA Fentanyl with the FDA for marketing approval,” said Nutriband CEO Gareth Sheridan in the press release. “This is a significant step for the company as we target this submission in Q1 2025.”

To view the full press release, visit https://ibn.fm/jRQwQ

About Nutriband Inc.

Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. The company’s lead product under development is an abuse-deterrent fentanyl patch incorporating its AVERSA(TM) abuse-deterrent technology. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion and accidental exposure of drugs with abuse potential. For more information about the company, please visit www.Nutriband.com.

NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in Nutriband Inc. NTRB | Leave a comment

MissionIRNewsBreaks – Diamond Lake Minerals Inc. (DLMI), BOXABL Partner to Make ‘Quite the Impact’ in Affordable Housing Market

Posted on April 18, 2024 by MissionIR

Diamond Lake Minerals (OTC: DLMI), a forward-thinking multi-strategy operating company specializing in digital assets and SEC-registered security tokens, today announced the beginning of its long-term real estate vision and working relationship with Boxabl, Inc. (“BOXABL”), a revolutionary modular home building company. According to the announcement, the partnership with DLMI “further expands the use cases of BOXABL where together they can identify, design and develop beautiful communities, known as BOXABL Villages.” The announcement further noted that DLMI’s leadership and position on the future of finance through security tokens, combined with all traditional means, will create additional unique opportunities for these villages to thrive and scale. Brian J. Esposito, CEO of Diamond Lakes Minerals, said, “I am also very excited to share this monumental day with our loyal and growing DLMI shareholders. DLMI and BOXABL working together to develop not only the BOXABL Village Concept, but also utilizing the large reach and influence we have created here at DLMI to provide solutions to affordable housing. The crisis that the housing market industry is experiencing is in desperate need of a realistic, attainable fix. I truly believe that BOXABL is the first modular home company to crack the code on this, and together we intend on making quite the impact.”

To view the full press release, visit https://ibn.fm/lpmxQ

About Diamond Lake Minerals Inc.

Founded in Utah in 1954, Diamond Lake Minerals is a multi-strategy operating company that specializes in the development and support of digital assets and SEC-registered security tokens. Its goal is to responsibly innovate and develop valuable traditional businesses and successfully combine them with the future of money and digital assets. The company’s mission is to bring back to the public markets timeless business principles that are focused on healthy sustainable growth and strong earnings that generate yields combined in a modern digital world creating value for its stakeholders. DLMI is positioning itself as an industry-agnostic leader in the digital asset and security token space. For more information, visit the company’s website at www.DiamondLakeMinerals.com.

NOTE TO INVESTORS: The latest news and updates relating to DLMI are available in the company’s newsroom at https://ibn.fm/DLMI

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in Diamond Lake Minerals Inc. DLMI | Leave a comment

MissionIRNewsBreaks – Zoned Properties Inc. (ZDPY) Featured in Bell2Bell Podcast

Posted on April 18, 2024 by MissionIR

Zoned Properties (OTCQB: ZDPY), a technology-driven property investment company for emerging and highly regulated industries, was featured in the latest episode of the Bell2Bell Podcast as part of IBN’s sustained effort to provide specialized content distribution via widespread syndication channels. Bryan McLaren, chairman and CEO of Zoned Properties, joined the program to provide an overview of the company’s business model and how his experience translates into the regulated cannabis space. “Zoned Properties, based in Scottsdale, Arizona, is focused on real estate and the regulated cannabis industry. Zoned Properties is essentially a technology-driven property investment company. We look at state-by-state markets that have legalized and regulated cannabis – that’s a huge emerging and growing industry,” McLaren said in the interview. “Our company and our team go into these state marketplaces, and we identify, qualify and get these properties approved that can be utilized as regulated cannabis facilities.”

To view the full press release, visit https://ibn.fm/byZ94

About Zoned Properties Inc.

Zoned Properties is a technology-driven property investment company focused on acquiring value-add real estate within the regulated cannabis industry in the United States. The company aspires to innovate within the real estate development sector, focusing on direct-to-consumer real estate that is leased to the best-in-class cannabis retailers. Headquartered in Scottsdale, Arizona, Zoned Properties is redefining the approach to commercial real estate investment through its standardized investment process backed by its proprietary property technology. Zoned Properties has developed a national ecosystem of real estate services to support its real estate development model, including a commercial real estate brokerage and a real estate advisory practice. With a decade of national experience and a team of experts devoted to the emerging cannabis industry, Zoned Properties is addressing the specific needs of a modern market in highly regulated industries. The company targets commercial properties that face unique zoning or development challenges, identifies solutions that can potentially have a major impact on their commercial value, and then works to acquire the properties while securing long-term, absolute-net leases. Zoned Properties targets commercial properties that can be acquired and rezoned for specific purposes, including the regulated and legalized cannabis industry. It does not grow, harvest, sell or distribute cannabis or any substances regulated under United States law. For more information, visit the company’s website at www.ZonedProperties.com.

NOTE TO INVESTORS: The latest news and updates relating to ZDPY are available in the company’s newsroom at https://ibn.fm/ZDPY

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in Zoned Properties Inc. ZDPY | Leave a comment

SuperCom Ltd. (NASDAQ: SPCB) Delivers Solutions for Responding to Stalking Threats on Global Basis

Posted on April 18, 2024 by MissionIR
  • SuperCom Ltd. is a digital security solutions innovator focused on the market for monitoring criminal offenders and tracking for public security
  • A popular streaming show, as well as media reports on real-life cyberstalker threats, have increased public awareness of the limitations of criminal justice systems worldwide to stop stalking offenders from continuing their activities
  • SuperCom’s RFID and GPS-enabled solutions help to identify the movements of offenders as part of the electronic security surveillance market, which is expected to grow to $2.3 billion during the next five years
  • SuperCom is growing in the European Union through recent new contracts in Romania and Finland, but is most focused on the United States market opportunities, fulfilling contracts in select states

The advent of the Internet, and increasingly smart computerized technology, has made the world an interconnected place, granting powerful informational tools to help people meet daily challenges.

However, those same tools can also be used abusively by bad players, including domestic violence and other offenders acting as cyberstalkers with malicious intent. A report by social justice media outlet Reckon notes that about a third of all women and a sixth of all men have been stalked at some point — usually by an acquaintance or former partner, but sometimes by a stranger. The report cites statistics showing that about 80 percent of stalking victims report that technology was used to monitor them, threaten them, or cause damage to their reputations (https://ibn.fm/ZnqxR).

A recent Netflix docuseries “Can I Tell You a Secret?” has drawn millions of viewers into the real-life travails of three women targeted for more than a decade by an English cybercriminal, highlighting the limitations of overall legal and criminal justice systems in stopping such criminals from continuing their behavior (https://ibn.fm/S67sy). A TikTok influencer’s current cyberstalking dilemma (https://ibn.fm/g4f6M), as well as the continuing property intruder difficulties plaguing billionaire pop star Taylor Swift (https://ibn.fm/rCAn4), have shown that such legal limitations appear to be an ongoing concern.

Electronic-monitoring security solutions developer SuperCom (NASDAQ: SPCB) is devoted to using technology to limit the threat of stalking-related violence by working with criminal justice systems, consumers, and government-level security experts, and providing effective monitoring, offender tracking, and rehabilitation reinforcement programs to promote public safety.

The company is currently employing its innovative PureOne solution to deliver an all-in-one field-proven RFID & mobile technology and product suite that is growing with the addition of GPS technologies.

“Our partnership’s expansion into GPS technology with our PureOne devices marks a notable achievement for SuperCom,” SuperCom CEO and President Ordan Trabelsi stated in January (https://ibn.fm/ABW7J). “This project exemplifies our dedication to delivering cutting-edge technology and reinforces our position as a leader in the electronic monitoring industry.”

SuperCom’s most recent quarterly financials filing reported revenue growth of 67 percent year-over-year, with 73 percent of revenues recurring. While the company is focused on opportunities in the United States, it operates globally.

“Our steadfast commitment to advancing public safety through technology resonates with governments and agencies worldwide as evidenced by the continued expansion in Finland and our growing partnership with Romania’s Ministry of Interior,” Trabelsi stated in November (https://ibn.fm/b8iGJ).

The market for court-ordered monitoring of inmates and individuals participating in rehabilitation programs is expected to reach $2.3 billion by 2029, growing at a CAGR of 9.5 percent during the next five years, according to Mordor Intelligence analysts (https://ibn.fm/6xTin).

“A 5-year record net profit, remarkable 550% growth in EBITDA and 74% growth in gross profit margins, are clear indicators of the successful execution of our growth strategy,” Trabelsi stated in November. “As we look to the future, SuperCom is uniquely positioned to capitalize on the increasing global demand for secured electronic monitoring solutions.”

For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in SuperCom Ltd. SPCB | Leave a comment